Home Latest Articles
Latest Articles
  • Yu CHEN, Gang FANG, Wei LI, Jinxi DING
    World Clinical Drug. 2026, 47(7): 795-801.
    Objective

    To evaluate the cost-effectiveness of recombinant human TNK tissue-type plasminogen activator(TNK) versus alteplase in adult patients with acute ischemic stroke from the perspective of Chinese health system.

    Methods

    Based on individual patient data from the phase Ⅲ clinical trial TRACE-2(NCT04797013) of TNK in China, a decision tree and Markov hybrid model was constructed to simulate both a 1-year short-term and a lifetime horizon. The incremental cost-effectiveness ratio(ICER) of TNK versus alteplase was calculated, and sensitivity analysis were performed to test the robustness of the results.

    Results

    Compared with alteplase, TNK provided an incremental gain of 0.016 quality-adjusted life years(QALYs) and saved 65.29 yuan over a 1-year horizon, and provided 0.118 QALYs gained and saved 2 306.68 yuan over the lifetime horizon. TNK was dominant over alteplase in both time horizons.

    Conclusion

    From the perspective of the Chinese health system, TNK is cost-effective compared with alteplase for adult patients with acute ischemic stroke in China.

  • Jingchao LI, Jianjun CHEN, Wei JIA, Guanchun HUA, Li MI
    World Clinical Drug. 2026, 47(7): 802-809.

    Hyperlipidemia is an important risk factor for cardiovascular and cerebrovascular diseases, and its pathogenesis involves abnormal regulation of multiple key signaling pathways. Traditional Chinese medicine has the advantages of multi-target and multi-pathway in regulating lipid metabolism and improving hyperlipidemia. By intervening in signaling pathways such as adenosine monophosphate activated protein kinase, peroxisome proliferator activated receptor, sterol regulatory element binding protein, liver X receptor, and nuclear factor-κB, it can effectively regulate the synthesis and metabolism of cholesterol and triglycerides. This article reviewed the regulatory mechanisms and experimental research progress of traditional Chinese medicine compound formulas on hyperlipidemia related signaling pathways, providing theoretical basis for clinical applications and new drug development.

  • Lili YU, Xiaomei HE, Tongfei LI, Peng CHEN, Ping HUANG, Yingqiang LI
    World Clinical Drug. 2026, 47(7): 810-817.

    Dihydroartemisinin(DHA), as a first-line antimalarial drug, exhibits better pharmacokinetic characteristics compared to artemisinin, including higher absorption efficiency, broader tissue distribution, and lower toxicity. As the multi-target anti-tumor mechanism of DHA has gradually become clear, it has been regarded as a repurposed anti-tumor candidate with translational potential. DHA can inhibit the proliferation, invasion and metastasis of tumor cells, and induce apoptosis and autophagy. It can also regulate the tumor microenvironment(TME), inhibit angiogenesis, interfere with the functions of cancer-associated fibroblasts, and reshape the signal transmission between immune cells, thereby weakening tumor immunosuppression. This review summarized the specific roles of DHA in the TME, and demonstrated that DHA, as a potential anti-tumor drug, held significant clinical value.

  • Qingxiu SUN, Fenghua PU
    World Clinical Drug. 2026, 47(7): 818-824.

    Human epidermal growth factor receptor(HER)2 positive breast cancer is a specific type of breast cancer that typically has a higher invasiveness and poorer prognosis. Targeted drugs such as trastuzumab and pertuzumab can specifically bind to HER2 receptors, inhibit the growth and spread of cancer cells, and prolong the survival of patients.traditional Chinese medicine(TCM), as a precious treasure of the nation, having accumulated rich experience in the treatment of breast cancer. It could enhance clinical treatment outcomes, reduce adverse reactions, improve patients'immune function, serve as an important complementary approach to breast cancer treatment. The combination of targeted drugs with TCM has achieved good results in the treatment of HER2 positive breast cancer. Based on the current situation of traditional Chinese medicine combined with targeted drugs in the treatment of HER2 positive breast cancer, this paper analyzed and summarized existing studies to provide a reference for comprehensive clinical treatment of breast cancer..

  • Xingxing XIE, Pei WANG, Ming HU
    World Clinical Drug. 2026, 47(7): 825-830.
  • Honglei WU, Danying YAN, Niansong WANG, Junhui LI
    World Clinical Drug. 2026, 47(6): 589-594.

    Refractory nephrotic syndrome(RNS) is a subtype of primary NS with high treatment difficulty, mainly including steroid-resistant NS and steroid-dependent/frequently relapsing NS. Traditional immunosuppressants have limited efficacy and insufficient safety, which can hardly meet current clinical demands. Anti-CD20 monoclonal antibody(anti-CD20McAb) has shown outstanding performance in the treatment of RNS due to its targeting specificity. This review focuses on anti-CD20McAb drugs, including rituximab, ofatumumab, and obinutuzumab, analyzes their related mechanisms of action, as well as the clinical efficacy and differences among common pathological types of RNS, to provide a reference for clinical practice.

  • Liang ZHANG, Wei ZHANG, Niansong WANG
    World Clinical Drug. 2026, 47(6): 595-600.

    Nephrotic syndrome(NS) is a group of clinical syndromes characterized by massive proteinuria and complicated pathogenesis, and its treatment strategies urgently require a breakthrough. In recent years, abnormal activation of the complement system has been confirmed as a key link leading to damage to the glomerular filtration barrier, and targeted therapy against specific complement components has become a cutting-edge research direction in nephrology. This review focuses on the core role of complement component 5a and its receptor axis, mannan-binding lectin serine protease 2 of the lectin pathway, and the alternative pathway in driving NS progression, summarizes the clinical advances of related pathway inhibitors, and discusses their therapeutic potential, the available evidence, and future research directions.

  • Dan MAO, Li CHEN, Wei CHANG, Congcong ZHANG, Yinling LI, Xiaohui SUO
    World Clinical Drug. 2026, 47(6): 601-612.
    Objective

    To investigate the effect and mechanism of lysine demethylase 5B(KDM 5B) on the biological function of acute myeloid leukemia(AML) cells.

    Methods

    Peripheral blood and bone marrow samples were collected from 23 AML patients and 20 healthy donors, and the expression levels of KDM5B were compared. The AML cells HL-60 were transfected with KDM5B short hairpin RNA (shRNA) (sh-KDM5B), overexpression vector(KDM5B), cathepsin F shRNA(sh-CTSF) and overexpression vector(CTSF), as well as B-cell lymphoma-2 shRNA(sh-BCL-2). Chromatin Immunoprecipitation(ChIP) was employed to analyze the binding of KDM5B to the promoter region of CTSF, while Co-immunoprecipitation (CoIP) was used to investigate the interaction between CTSF and BCL-2 proteins. The CCK-8 assay and Transwell experiment were used to detect the proliferation and invasion abilities of the cells, while flow cytometry was employed to analyze the number of apoptotic cells.

    Results

    The expression of KDM5B in the peripheral blood and bone marrow samples of AML patients was significantly higher than that in healthy donors(P<0.01). The expression of KDM5B in AML cells(HL-60, ML-1) was significantly higher than that in human bone marrow cells HS-27A(P<0.01). Silencing KDM5B significantly inhibited the proliferation and invasion of AML cells and induced cell apoptosis(P<0.01). KDM5B bound to the promoter of CTSF and upregulated the expression of CTSF. The upregulated CTSF then interacted with BCL-2 protein to inhibit its protein expression. Silencing CTSF inhibited cell proliferation and invasion, and induced cell apoptosis(P<0.01). Silencing BCL-2 can counteract the effects of CTSF silencing on AML cells(P<0.05).

    Conclusion

    KDM5B is significantly upregulated in AML. Its overexpression promotes the proliferation and invasion of AML cells and inhibits cell apoptosis by upregulating the expression of CTSF and inhibiting the expression of BCL-2.

  • Jing GUO, Yizhou WANG
    World Clinical Drug. 2026, 47(6): 613-618.
    Objective

    To investigate the effect of Xiangsha Liujunzi decoction combined with tegoprazan on gastrointestinal dynamics in patients with reflux esophagitis(RE).

    Methods

    A total of 100 RE patients admitted in Linquan county people's hospital from February 2023 to March 2025 were selected and divided into the control group and the observation group by simple random sorting method, with 50 cases in each group. The control group was treated with mosapride citrate capsules combined with tegoprazan, while the observation group was treated with Xiangsha Liujunzi decoction combined with tegoprazan. Both groups were treated for 8 weeks. The efficacy, gastrointestinal motility indexes, inflammatory indexes, and scores of the Reflux Disease Questionnaire(RDQ) and Gastroesophageal Reflux Disease Questionnaire(GerdQ) were compared between the two groups.

    Results

    After treatment, the total effective rate of the observation group was higher than that of the control group(90.00% vs. 82.00%). After treatment, the gastrointestinal motility indexes and inflammatory indexes of both groups were improved compared with those before treatment(P<0.05), and the levels of gastrin, motilin, cholecystokinin, tumor necrosis factor-α, interleukin-6, interleukin-17 and gastric emptying time in the observation group were better than those in the control group(P<0.05). The reflux symptoms of both groups were improved compared with those before treatment, and the scores of RDQ and GerdQ in the observation group were lower than those in the control group(P<0.05). There was no significant difference in the incidence of complications between the two groups(P>0.05).

    Conclusion

    Xiangsha Liujunzi decoction combined with tegoprazan can effectively promote the recovery of gastrointestinal motility, relieve clinical symptoms and reduce inflammatory response in RE patients, with significant curative effect.

  • Li ZHANG, Xiao DU, Xiaoli QIAO
    World Clinical Drug. 2026, 47(6): 619-625.
    Objective

    To investigate the preventive effect of low-dose esketamine on catheter-related bladder discomfort(CRBD) in patients during anesthesia recovery period.

    Methods

    A total of 300 patients with benign prostatic hyperplasia admitted to our hospital from June 2021 to December 2024 were prospectively selected as the research subjects. The patients were divided into the control group and the observation group using simple sorting random method, with 150 patients in each group. The control group was intravenously injected with an equal volume of 0.9% sodium chloride solution after anesthesia induction, while the observation group was intravenously injected with a low dose of esketamine(0.25mg/kg). All included patients underwent transurethral prostatectomy treatment. The indicators related to CRBD and postoperative pain control were recorded. The secondary observation indicators included multiple dimensions such as perioperative rehabilitation and monitoring, drug safety, biological parameters, and long-term follow-up of urinary function.

    Results

    The indicators related to CRBD, postoperative pain control and early rehabilitation, as well as the levels of neurotransmitters(such as substance P and acetylcholine) at 1 hour and 24 hours after extubation, and inflammatory factors(such as interleukin-6 and tumor necrosis factor-α) and the urinary function indicators(such as international prostate symptom score, residual urine volume, and maximum urine flow rate) at 1 month and 3 months after surgery in the observation group were all better than those in the control group(P<0.05), while there were no statistically significant differences in the operation time, bladder capacity at 24 hours after surgery, and the incidence of adverse drug reactions between the two groups(P>0.05).

    Conclusion

    Low-dose esketamine can effectively reduce the incidence and severity of CRBD in patients undergoing transurethral prostatectomy during the anesthesia recovery period, optimize postoperative pain control and early rehabilitation indicators, regulate neurotransmitter and inflammatory factor levels, and does not increase adverse drug reactions, and facilitate the recovery of bladder function after surgery.

News